POLBF (Poolbeg Pharma) Common Stock: $0.19 Mil (As of Dec. 2025)


What is Poolbeg Pharma Common Stock?

Poolbeg Pharma POLBF Common Stock is $0.19 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Poolbeg Pharma's quarterly common stock increased from Dec. 2024 ($0.13 Mil) to Jun. 2025 ($0.19 Mil) but then declined from Jun. 2025 ($0.19 Mil) to Dec. 2025 ($0.19 Mil).

Poolbeg Pharma's annual common stock declined from Dec. 2023 ($0.13 Mil) to Dec. 2024 ($0.13 Mil) but then increased from Dec. 2024 ($0.13 Mil) to Dec. 2025 ($0.19 Mil).

Poolbeg Pharma Common Stock Historical Data

* Premium members only.

The historical data trend for Poolbeg Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poolbeg Pharma Common Stock Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
0.13 0.12 0.13 0.13 0.19

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only 0.13 0.13 0.13 0.19 0.19

Poolbeg Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.19 Mil mean?
Poolbeg Pharma (POLBF) has a Common Stock of $0.19 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Poolbeg Pharma and its competitors.
Is Poolbeg Pharma's Common Stock too high?
Poolbeg Pharma's current Common Stock is $0.19 Mil.
How does Poolbeg Pharma's Common Stock compare to VRTX and REGN?
Poolbeg Pharma's Common Stock of $0.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Poolbeg Pharma and its competitors. Poolbeg Pharma's current Common Stock is $0.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Common Stock of $0.19 Mil. The current Common Stock is $0.19 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Common Stock is $0.19 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.